• Quince received a Nasdaq notice on Aug. 31, 2026 for failing the $10 million minimum stockholders’ equity rule.
• Stockholders’ equity was negative USD 35.32 million in its Form 10-Q for the quarter ended June 30, 2026.
• Shares keep trading on Nasdaq Global Select Market under QNCX with no immediate impact.
• Company must submit a compliance plan by Oct. 15, 2026; Nasdaq may extend the cure period to Feb. 27, 2027.
• Company is weighing options, including a proposed name change to IRulya Therapeutics with a planned move to Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-382838), on September 04, 2026, and is solely responsible for the information contained therein.